Evidence map›Paper›PMID 42604059›Full record

ReviewThe Lancet regional health. Europe2026

Crisis readiness for rare disease populations: learnings and recommendations by the European Reference Networks.

Hélène Dollfus, Alexis Arzimanoglou, Teresinha Evangelista, Holm Graessner, Marta Mosca, Luca Sangiorgi, Jean-Yves Blay, Christine Bodemer, Pierre Fenaux, Francisco Hernández and 15 more

Abstract readReview
In one paragraph

Review in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Hélène DollfusERN-EYE, FSMR SENSGENE, Centre de Référence pour les Affections Rares en Génétique Ophtalmologique (CARGO), IGMA, Hôpitaux Universitaires de Strasbourg, Université de Strasbourg, Strasbourg, France.
Alexis ArzimanoglouERN EpiCARE Coordinator, Child Neurology and Epilepsy Department, Children's University Hospital San Juan de Dios and IRSJD, Barcelona, Spain.
Teresinha EvangelistaERN EURO-NMD, Department of Neuropathology, Nord/Est/Ile-de-France Neuromuscular Reference Center, Pitié-Salpêtrière Hospital, APHP, Sorbonne University, Paris, France.
Holm GraessnerERN-RND, University Hospital Tübingen, Institute for Medical Genetics and Applied Genomics and Center for Rare Diseases, Tübingen, Germany.
Marta MoscaERN ReCONNET, Rheumatology Unit, Azienda Ospedaliero-Universitaria Pisana, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Luca SangiorgiERN BOND, Department of Rare Skeletal Disorders, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Jean-Yves BlayERN EURACAN, Centre Léon Bérard, & Université Claude Bernard Lyon I, Lyon, France.
Christine BodemerERN-Skin, Department of Dermatology, Expert Centre for rare Skin Disorders, Necker-Enfants Malades Hospital, APHP, Paris-Cité University, Paris, France.
Pierre FenauxERN-EuroBloodNet, Service Hématologie Seniors, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris and Université Paris Cité, Paris, France.
Francisco HernándezERN TransplantChild, Department of Pediatric Surgery, La Paz University Hospital, Madrid, Spain.
Guillaume JondeauERN VASCERN, Reference Center for Marfan Syndrome and Related Diseases, Cardiology Department, APHP, Hospital Bichat, Université Paris Cité, INSERM, Paris, France.
Marjolijn J L LigtenbergERN GENTURIS, Department of Human Genetics, Department of Pathology, Research Institute for Medical Innovation, Radboud University Medical Center, Nijmegen, the Netherlands.
Ansgar W LohseERN RARE-LIVER, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Irene M J MathijssenERN CRANIO, Department of Plastic and Reconstructive Surgery and Hand Surgery, Erasmus University Medical Center Rotterdam, the Netherlands.
Peter MuldersERN eUROGEN, Department of Urology, Radboud University Medical Center, Nijmegen, the Netherlands.
Alberto M PereiraEndo-ERN, Department of Endocrinology and Metabolism, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Franz SchaeferERN ERKNet, Division of Pediatric Nephrology, Department of Pediatrics, University of Heidelberg, Heidelberg, Germany.
Joost F SwartERN RITA, Department of Pediatric Immunology and Rheumatology, Wilhelmina Children's Hospital/UMC Utrecht, Utrecht, the Netherlands.
Alain VerloesERN ITHACA, Department of Genetics, APHP-Robert DEBRE University Hospital, Université Paris Cité Medical School, Paris, France.
Thomas O F WagnerERN-LUNG, Frankfurt Reference Center for Rare Diseases (FRZSE), University Hospital Frankfurt, Goethe University Frankfurt, Frankfurt am Main, Germany.
René M H WijnenERN ERNICA, Department of Pediatric Surgery, Erasmus MC Sophia, Rotterdam, the Netherlands.
Arthur A M WildeERN GUARD-Heart, Department of Clinical Cardiology, Amsterdam University Medical Centre (location AMC), Amsterdam, the Netherlands.
María Del Mar Mañú PereiraERN-EuroBloodNet, Hematology Research Group, Vall D'Hebron Research Institute, Barcelona, Spain.
Ruth LadensteinERN PaedCan Coordinator and Chair Coordinator's Group, St Anna Children's Hospital and Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria.
Maurizio ScarpaMetabERN Coordinator, Regional Coordinating Centre for Rare Diseases, University Hospital Udine, Udine, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with rare diseases are particularly vulnerable during emergencies due to dependence on specialised care pathways, medicines, and expertise. European Reference Networks (ERNs) for rare and complex diseases have operated since 2017 and were confronted with two major crises: the COVID-19 pandemic and the war in Ukraine. To assess ERN experiences, responses, and preparedness for crisis and disaster situations, we conducted a cross-sectional survey of all 24 ERN coordinators between July and September 2025. Only 2 (8·3%) ERNs reported pre-existing preparedness plans, while 70% lack structured frameworks. Major bottlenecks included patient access to healthcare facilities, drug and device shortages, bed shortage, staff unavailability, and diagnostic service interruption. Our findings highlight the need to formally integrate and mandate ERNs into European health emergency preparedness and response mechanisms. We propose a 10-point global crisis preparedness plan for rare diseases emphasizing cross-border coordination, digital infrastructure, patient education, and integration with national emergency services and non-governmental organizations.

Indexed as

Climate changeContinuity of careCrisis preparednessCross-border healthcareEuropean Reference NetworksHealthcare pathwaysHealth emergency responseHealth system resiliencePandemicsRare diseases

Identifiers

PMID42604059
PMCPMC13476765

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.